High grocery prices got droves of Americans to vote for Trump but they shouldn’t expect to pay less over the next four years

Donald Trump highlighted rising costs during his campaign to return to the White House.Jeenah Moon/Reuters New YorkCNN  —  Americans are shelling out 22% more for groceries compared to when President Joe Biden took office in January 2021, according to October Consumer Price Index inflation data. While wages finally began to outpace the rate at which…

Read More

Small businesses are hurting at the worst possible time

Enjou Chocolat’s seasonally themed chocolates and baskets displayed at the store in Morristown, New Jersey, on November 11.Courtesy Enjou Chocolat WashingtonCNN  —  Enjou Chocolat, a small business in Morristown, New Jersey, is still feeling the pain of inflation these days — from soaring cocoa prices to increased labor expenses. As a result, the chocolate shop,…

Read More

‘A lot of fear:’ Trump’s deportation proposals are already rattling workers

Restaurants could be among the businesses hardest hit by President-elect Donald Trump’s plans for mass deportation.10’000 Hours/Digital Vision/Getty Images CNN  —  President-elect Donald Trump’s promise to further restrict immigration and roll out“mass deportations” has not been finalized, but the specter of looming policy changes is already reverberating on Main Streets across America. To veteran restaurateur…

Read More

Baidu shares slide as Barclays downgrades on ad revenue outlook

Investing.com — Baidu (NASDAQ:BIDU) US-listed shares fell nearly 3% in premarket trading Friday after Barclays (LON:BARC) analysts downgraded the stock to Equal Weight from Overweight and cut the price target from to $83 from $115. The revision comes amid pressures from the Chinese internet giant’s growing focus on generative AI, which “exacerbates pressure” on advertising…

Read More

Barclays says buy Novo Nordisk stock ‘into this critically important catalyst’

Investing.com — Barclays analysts are bullish on Novo Nordisk (NYSE:NVO) stock ahead of the December release of pivotal clinical trial data for its next-generation obesity treatment, CagriSema. The results of the REDEFINE-1 Phase 3 trial could, according to Barclays (LON:BARC), “redefine the obesity landscape” and provide a much-needed boost to the company’s stock, which has faced…

Read More